Koers Cyxone AB (publ) Nasdaq Stockholm
Aandelen
SE0007815428
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 19,22 mln. 1,78 mln. 1,65 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -28 mln. -2,59 mln. -2,4 mln. | Nettowinst (verlies) 2025 * | -38 mln. -3,51 mln. -3,26 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 1 mln. 92,46K 85,89K | Nettoliquiditeiten 2025 * | 41 mln. 3,79 mln. 3,52 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,68
x | K/w-verhouding 2025 * |
-0,49
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,97% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 54 | 20-05-21 | |
Founder | 58 | 01-01-15 | |
Malin Lindskog
DFI | Director of Finance/CFO | 63 | 15-06-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 58 | 01-01-15 | |
Director/Board Member | 58 | 01-01-15 | |
Michael Oredsson
CHM | Chairman | 64 | 01-01-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,48% | 69,91 mld. | |
+12,55% | 9,24 mld. | |
-13,75% | 5,05 mld. | |
+42,38% | 4,47 mld. | |
+4,51% | 3,92 mld. | |
-19,05% | 2,41 mld. | |
-28,72% | 2,23 mld. | |
+11,13% | 2,02 mld. | |
+6,53% | 1,66 mld. |